Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Aclarion Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ACON
Nasdaq
8731
https://aclarion.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Aclarion Inc
Aclarion's Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain
- Apr 25th, 2024 1:16 pm
Aclarion to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024
- Apr 23rd, 2024 12:00 pm
Aclarion Announces Publication of Compelling Peer-Reviewed Data in International Journal of Spine Surgery Supporting Nociscan as a Gold Standard for Noninvasive Identification of Painful Lumbar Discs
- Mar 4th, 2024 1:00 pm
Aclarion Announces Closing of $3.0 Million Public Offering
- Feb 27th, 2024 8:27 pm
Aclarion Announces Pricing of $3.0 Million Public Offering
- Feb 26th, 2024 2:15 pm
Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership
- Feb 5th, 2024 1:00 pm
Thinking about buying stock in Spectral AI, Applied UV, Adobe, BigBear.ai, or Aclarion?
- Jan 29th, 2024 2:31 pm
Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD
- Jan 22nd, 2024 1:00 pm
Aclarion Announces Updated Product Release That Expands MRI Scanner Access for Nociscan Solution
- Jan 17th, 2024 1:00 pm
Aclarion and ATEC Execute Strategic Partnership Agreement to Advance Commercialization of Nociscan
- Jan 8th, 2024 1:00 pm
Aclarion Announces Reverse Stock Split
- Jan 2nd, 2024 5:00 pm
Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams
- Nov 27th, 2023 1:00 pm
Aclarion Announces Achievement of Goal to Enroll 10 Leading Spine Surgery Key Opinion Leaders (KOLs) to Support Nociscan Adoption
- Nov 8th, 2023 1:00 pm
Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MD
- Nov 6th, 2023 1:00 pm
Aclarion Presents at the NIH HEAL Initiative Fall Meeting
- Nov 1st, 2023 12:00 pm
Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to Denver
- Oct 25th, 2023 12:30 pm
Aclarion Announces Nociscan® Cost-Effectiveness Poster Presented at 45th Annual SMDM Meeting
- Oct 24th, 2023 12:45 pm
Aclarion Announces Signing Strategic Partnership Letter of Intent With ATEC to Advance Commercialization of Nociscan
- Oct 23rd, 2023 11:00 am
Aclarion Provides Updated Investor Presentation and Corporate Update
- Oct 2nd, 2023 12:00 pm
Scroll